Heart failure (HF) remains the leading cause of hospitalization in older adults and is associated with increased morbidity and mortality despite the use of guideline-directed medical therapy. There has been tremendous progress in the development of novel transcatheter and interventional therapies for HF over the past decade. The evolution of structural heart disease interventions and interventional HF has led to a multidisciplinary heart team approach in the management of HF patients. Careful selection of the appropriate patient population and end points in future randomized controlled trials will be crucial to demonstrate the potential efficacy of the novel interventional HF therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hfc.2017.02.009 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!